Key Points {#FPar1}
==========

The RE-DUAL PCI trial investigated patients with atrial fibrillation post-percutaneous coronary intervention. Dabigatran dual therapy (DDT) reduced bleeding risk vs warfarin triple therapy (WTT)This subanalysis investigated patients categorized according to proton pump inhibitor use at baselineClinical efficacy endpoints were similar in DDT and WTT groups regardless of proton pump inhibitor use. DDT reduced bleeding risk vs WTT regardless of proton pump inhibitor use

Introduction {#Sec1}
============

Proton pump inhibitors (PPIs) are recommended for the prevention of gastrointestinal (GI) bleeding in cardiovascular patients receiving antithrombotic therapy, especially in those with a higher risk of bleeding \[[@CR1], [@CR2]\]. Proton pump inhibitors reduce bleeding events when administered with aspirin \[[@CR3]\] or clopidogrel \[[@CR4]\]; however, results are conflicting on the interactions of PPIs with antiplatelet drugs and effects on clinical outcomes \[[@CR5]--[@CR7]\], and there are concerns regarding their cardiovascular safety \[[@CR8], [@CR9]\]. The Clopidogrel and the Optimization of Gastrointestinal Events Trial is the only randomized study testing PPIs in patients taking dual antiplatelet therapy (DAPT) with aspirin and clopidogrel and, despite the limitations of the trial (mainly the low number of events and the final reduced sample size), it suggested that use of omeprazole reduces upper GI bleeding in patients receiving DAPT, without an increase in cardiovascular events \[[@CR10]\].

Proton pump inhibitors are also expected to reduce the risk of GI bleeding in patients receiving oral anticoagulation therapy, as suggested by observations in subjects treated with warfarin \[[@CR11]\] and direct oral anticoagulants (DOACs) \[[@CR12]\], including dabigatran \[[@CR13]\]. Specifically, in patients with atrial fibrillation (AF) who underwent recent percutaneous coronary intervention (PCI), clinical practice guidelines recommend (except in patients with a very high risk of bleeding and a low risk of ischemic events) triple antithrombotic therapy with DAPT and an anticoagulant agent. This regimen further increases the bleeding risk in this population \[[@CR1], [@CR2], [@CR14]\]. Regarding dabigatran, a 15% decrease in drug exposure by PPI use was found in the Randomized Evaluation of Long-term Anticoagulant Therapy (RE-LY) trial, without an observable impact on efficacy or safety \[[@CR15]\].

The randomized RE-DUAL PCI trial compared dual antithrombotic therapy with dabigatran 110 or 150 mg twice daily (plus either clopidogrel or ticagrelor) with triple antithrombotic therapy with warfarin (plus aspirin and clopidogrel or ticagrelor) in patients with AF who underwent PCI \[[@CR16]\]. Dabigatran dual therapy reduced the risk of the primary endpoint of International Society on Thrombosis and Haemostasis (ISTH)---defined major bleeding events (MBEs) or clinically relevant non-major bleeding events (CRNMBEs) vs warfarin triple therapy, and was non-inferior for the main clinical efficacy endpoint \[[@CR16]\].

The effect of PPI administration in patients receiving both anticoagulant and antiplatelet therapies was not studied in the original publication, and it is not known whether the benefits in bleeding reduction with dabigatran dual therapy are valid both for patients taking and those not taking a PPI. This prespecified analysis of the RE-DUAL PCI trial was conducted to investigate whether PPI utilization at baseline could influence the main safety and efficacy results observed in the trial.

Methods {#Sec2}
=======

Patient Population {#Sec3}
------------------

The RE-DUAL PCI trial (NCT02164864) was a prospective multicenter international study that randomized 2725 patients to dabigatran dual therapy (plus clopidogrel or ticagrelor) or warfarin triple therapy (plus clopidogrel or ticagrelor and aspirin), including 1641 patients using PPIs at randomization. RE-DUAL PCI enrollment criteria, as well as the main trial results, have been published \[[@CR16], [@CR17]\]. Patients with paroxysmal, persistent, or permanent non-valvular AF who had undergone successful PCI in the previous 120 hours were eligible. Main exclusion criteria were the presence of creatinine clearance \< 30 mL/min, bioprosthetic or mechanical heart valve, or other major coexisting conditions, such as cardiogenic shock during the current hospitalization, GI bleeding in the previous month, acute liver disease, or contraindication to oral anticoagulation and/or antiplatelet therapy with clopidogrel, ticagrelor, or aspirin.

Patients from the USA and those aged \< 80 years (aged \< 70 years in Japan) were randomized to dabigatran 110 or 150 mg or warfarin in a 1:1:1 ratio. Patients outside the USA aged ≥ 80 years (aged ≥ 70 years in Japan) were randomized to the 110-mg dose of dabigatran vs warfarin in 1:1 ratio. In the warfarin triple-therapy group, aspirin was to be discontinued after 1 month in patients with a bare-metal stent implanted and after 3 months when a drug-eluting stent was implanted. All patients were to receive clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily) for ≥ 12 months after randomization; the choice of agent was left to the discretion of the investigator. Regarding PPI use, the study protocol stated: "The concomitant administration of PPI is strongly recommended in patients without clinical contraindications for those agents, to reduce the risk of GI bleeding. In patients receiving clopidogrel, PPIs that do not interact with the CYP2C19 (lansoprazole, pantoprazole, etc.) should be used".

For the present study, 2678 patients with complete data on PPI use at baseline (98.3% of the total randomized population) were analyzed. The main objective of this prespecified subgroup analysis was to evaluate if PPI use influenced the treatment effect of dabigatran dual vs warfarin triple therapy on ISTH MBEs or CRNMBEs. Secondary objectives included whether PPI use influenced the treatment effect of dabigatran dual vs warfarin triple therapy on ISTH MBEs, all GI bleeding, and all-cause mortality/thromboembolic event (DTE) or unplanned revascularization (clinical efficacy composite endpoint). A further objective was a treatment-independent evaluation (whole population), analyzing the influence of PPI utilization at baseline on bleeding and clinical efficacy composite endpoints.

Statistical Analyses {#Sec4}
--------------------

Baseline characteristics of the population are summarized for patients taking/not taking PPIs. Continuous variables are depicted as means (standard deviations) and categorical variables as counts (percentages).

Cox proportional hazard regression models stratified by age (non-elderly or elderly; \< 70 or ≥ 70 years in Japan and \< 80 or ≥ 80 years elsewhere) were utilized to compare dabigatran 110 mg dual therapy with warfarin triple therapy within PPI subgroup categories. Unstratified Cox proportional hazard regression models were utilized to compare dabigatran 150 mg dual therapy with warfarin triple therapy excluding elderly patients outside the USA. Exploratory treatment by PPI subgroup interaction *p* values were derived from Cox proportional hazard regression models stratified by age for dabigatran 110 mg dual therapy vs warfarin triple therapy and unstratified for dabigatran 150 mg dual therapy vs warfarin triple therapy. The same subgroup analysis was performed restricting the patient population to patients receiving clopidogrel at baseline.

Additionally, a multivariable adjusted Cox proportional hazard regression model was performed to compare treatment groups including treatment and PPI use at baseline as a factor as well as the interaction between treatment and PPI use at baseline. For bleeding endpoints, this Cox model was adjusted for known bleeding risk factors: continuous variables, age, and creatinine clearance; and categorical variables, prior MBE or bleeding predisposition, prior GI bleeding or ulcerative GI disease or gastritis, diabetes mellitus, aspirin at baseline, modified HAS-BLED score at baseline (\< 3 or ≥ 3), previous stroke, indication for PCI (acute coronary syndrome or elective PCI), and ticagrelor use at baseline. For the clinical efficacy composite endpoint, this Cox model was adjusted for known risk factors of DTE: continuous variables, age, and creatinine clearance; and categorical variables, prior myocardial infarction, diabetes, previous stroke, multi-vessel disease, indication for PCI, and ticagrelor use at baseline. The Cox model to compare dabigatran 110 mg dual therapy with warfarin triple therapy was stratified by age, whereas an unstratified Cox model was used to compare dabigatran 150 mg dual therapy with warfarin triple therapy.

To analyze the role of PPI utilization at baseline on clinical outcomes in the global population, a univariable, treatment-independent, Cox proportional hazard regression analysis stratified by age was developed (non-elderly vs elderly) including PPI use at baseline as the only factor in the model. A multivariable Cox proportional hazard regression analysis comparing risk of clinical outcomes between patients with and without PPI use at baseline was also performed. For bleeding endpoints, the Cox model was adjusted for the above-mentioned bleeding risk factors. For the clinical efficacy composite endpoint, the Cox model was adjusted for risk factors of all-cause mortality and thromboembolic events.

All statistical analyses were two-sided and a *p* value \< 0.05 was considered statistically significant. All *p* values are to be considered as exploratory. SAS 9.4 (SAS Institute Inc., Cary, NC, USA) was used for all statistical analyses.

Results {#Sec5}
=======

Of 2678 analyzed patients, 1641 (61.3%) used PPIs at baseline (Fig. 1 of the Electronic Supplementary Material \[ESM\]). Table [1](#Tab1){ref-type="table"} shows the characteristics of the population. Patients taking PPIs comprised a higher-risk population, being more frequently female and with a prior history of myocardial infarction, PCI, diabetes, hypertension, and GI bleeding. Mean CHA~2~DS~2-~VASc and modified HAS-BLED scores were similar between groups. Table 2 of the ESM shows the baseline characteristics of the population by PPI use and further split by treatment (i.e., eight groups). Regarding age, it is important to remember that patients outside the USA aged older than 79 years (aged older than 69 years in Japan) were precluded to receive dabigatran 150 mg dual therapy. As can be seen in Fig. 2 of the ESM, the percentage of patients taking PPIs was stable during the follow-up. For the 1641 patients taking PPIs at baseline, information on PPI use at the end-of-treatment visit was missing for 75 patients. Of the remaining 1566 patients, 1306 (83.4%) took PPIs at the end-of-treatment visit or since the last visit before the end of treatment. Of the 984 patients not using PPIs at baseline with available information at the end-of-treatment visit, 23.1% were taking PPIs at the end-of-treatment visit or since the last visit before the end of treatment (for 53 patients, information was missing at this visit).Fig. 1Safety and efficacy outcomes in patients receiving/not receiving proton pump inhibitors (PPIs) at baseline: dabigatran 110-mg dual therapy vs warfarin triple therapy. Hazard ratios (HRs) and 95% confidence interval (CIs) from the Cox proportional hazard model; stratified by age (elderly vs nonelderly). *CRNMBE* clinically relevant non-major bleeding event, *DTE* death/thromboembolic event, *ISTH* International Society on Thrombosis and Haemostasis, *MBE* major bleeding eventTable 1Characteristics of the RE-DUAL PCI population: proton pump inhibitor (PPI) vs no PPI at baselinePPI at baseline, yesPPI at baseline, noTotal (*n* = 1641)Total (*n* = 1037)Demographic data Age, mean (SD), years71.0 (8.7)70.4 (8.6) Male sex, *n* (%)1220 (74.3)813 (78.4) CrCl, mL/min, mean (SD)^a^76.5 (29.5)80.5 (29.3)Medical and surgical history Prior MI, *n* (%)458 (27.9)229 (22.1) Prior CAD, *n* (%)1096 (66.8)701 (67.6) Prior PCI, *n* (%)585 (35.6)311 (30) LV ejection fraction,^b^ mean (SD), %50.6 (12.3)51.7 (12.8) Heart failure, *n* (%)570 (34.7)350 (33.8) Diabetes mellitus, *n* (%)615 (37.5)358 (34.5) Hypertension, *n* (%)912 (55.6)479 (46.2) Currently smoking,^c^*n* (%)214 (13.0)120 (11.6) Previous GI bleeding, ulcerative GI disease, or gastritis, *n* (%)135 (8.2)44 (4.2) Prior major bleeding or predisposition to bleeding, *n* (%)18 (1.1)13 (1.3) CHA~2~DS~2~-VASc score, mean (SD)3.7 (1.6)3.5 (1.6) Modified HAS-BLED score, mean (SD)2.7 (0.7)2.7 (0.7)In-hospital approach Indication for PCI: ACS, *n* (%)875 (53.3)478 (46.1) Radial access,^d^*n* (%)1054 (64.2)649 (62.6) Only one coronary stent,^e^*n* (%)1326 (80.8)816 (78.7) Use of DES only,^f^*n* (%)1367 (83.3)843 (81.3) UFH use in index procedure, *n* (%)1396 (85.1)859 (82.8)Baseline medications Clopidogrel, *n* (%)1451 (88.4)880 (84.9) Statins1455 (88.7)879 (84.8) Oral hypoglycemic drugs430 (26.2)255 (24.6) ACE inhibitors912 (55.6)497 (47.9) Angiotensin receptor blockers535 (32.6)334 (32.2) β-blockers1387 (84.5)844 (81.4)Note, 47 patients with missing information on PPI use at baseline are excluded*ACE* angiotensin converting enzyme, *ACS* acute coronary syndrome, *CAD* coronary artery disease, *CrCl* creatinine clearance, *DES* drug-eluting stent, *GI* gastrointestinal, *LV* left ventricular, *MI* myocardial infarction, *PCI* percutaneous coronary intervention, *SD* standard deviation, *UFH* unfractionated heparin^a^Missing in 221 patients^b^Missing in 183 patients^c^Missing in one patient^d^Missing in 20 patients^e^Missing in 50 patients^f^Missing in seven patientsTable 2Safety and efficacy outcomes in patients receiving/not receiving proton pump inhibitors (PPIs) at baseline. Dabigatran dual therapy vs warfarin triple therapy: multivariable-adjusted analysesPPI at baselineDabigatran 110 mg dual therapy *n/N* (%)Warfarin triple therapy *n/N* (%)HR (95%)Dabigatran 150 mg dual therapy *n/N* (%)Warfarin triple therapy *n/N* (%)^b^HR (95%)Adjudicated ISTH MBE/CRNMBPPI89/549 (16.2)137/527 (26.0)0.64 (0.48--0.85)82/417 (19.7)106/405 (26.2)0.75 (0.54--1.03)No PPI48/323 (14.9)100/338 (29.6)0.52 (0.36*--*0.74)56/273 (20.5)73/267 (27.3)0.78 (0.54*--*1.13)Interaction *p* value0.34760.8640Adjudicated ISTH MBEPPI31/549 (5.6)45/527 (8.5)0.73 (0.44*--*1.20)22/417 (5.3)32/405 (7.9)0.65 (0.35*--*1.21)No PPI12/323 (3.7)32/338 (9.5)0.44 (0.22*--*0.88)14/273 (5.1)23/267 (8.6)0.63 (0.31*--*1.28)Interaction *p* value0.22040.9228Adjudicated GI bleedingPPI17/549 (3.1)24/527 (4.6)0.82 (0.42*--*1.59)15/417 (3.6)15/405 (3.7)0.83 (0.36*--*1.91)No PPI8/323 (2.5)15/338 (4.4)0.70 (0.29*--*1.71)7/273 (2.6)9/267 (3.4)0.71 (0.25*--*2.06)Interaction *p* value0.77920.8067Adjudicated DTE/unplanned revascularizationPPI93/544 (17.1)71/520 (13.7)1.25 (0.92*--*1.71)54/413 (13.1)56/398 (14.1)0.96 (0.66*--*1.40)No PPI43/327 (13.1)45/332 (13.6)0.95 (0.62*--*1.44)27/269 (10.0)30/265 (11.3)0.92 (0.54*--*1.55)Interaction *p* value0.28770.8954*CRNMBE* clinically relevant non-major bleeding event, *DTE* death/thromboembolic event, *GI* gastrointestinal, *HR* hazard ratio, *ISTH* International Society on Thrombosis and Haemostasis, *MBE* major bleeding event^a^See Sect. [2.2](#Sec4){ref-type="sec"} for details^b^For the comparison with dabigatran 150 mg dual therapy, elderly patients outside the USA are excludedFig. 2Safety and efficacy outcomes in patients receiving/not receiving proton pump inhibitors (PPIs) at baseline: dabigatran 150 mg dual therapy vs warfarin triple therapy. For the comparison with 150 mg dabigatran dual therapy, elderly patients outside the USA are excluded. Hazard ratios (HRs) and 95% confidence intervals (CIs) from the unstratified Cox proportional hazard model. *CRNMBE* clinically relevant non-major bleeding event, *DTE* death/thromboembolic event, *ISTH* International Society on Thrombosis and Haemostasis, *MBE* major bleeding event

Influence of Proton Pump Inhibitor Utilization at Baseline Regarding the Comparison of Dabigatran Dual vs Warfarin Triple Therapy {#Sec6}
---------------------------------------------------------------------------------------------------------------------------------

Dabigatran 110 and 150 mg dual therapy consistently reduced the risk of ISTH MBEs/CRNMBEs vs warfarin triple therapy regardless of PPI use, with a comparable risk for the composite efficacy endpoint.

Figure [1](#Fig1){ref-type="fig"} shows the population receiving dabigatran 110 mg dual therapy compared with warfarin triple therapy. Dabigatran 110 mg dual therapy considerably reduced the risk of bleeding events (ISTH MBE/CRNMBE, ISTH MBE alone) vs warfarin triple therapy, with a comparable risk of the clinical composite efficacy endpoint in both treatment groups, independent of PPI use at baseline (*p* values for interaction \> 0.05).

Figure [2](#Fig2){ref-type="fig"} analyzes the same parameters for the population receiving dabigatran 150 mg dual therapy. The group dabigatran dual therapy considerably reduced the risk of ISTH MBEs/CRNMBEs vs warfarin triple therapy with a comparable risk of the clinical composite efficacy endpoint, independent of PPI utilization (*p* values for interaction \> 0.05).

Figure [3](#Fig3){ref-type="fig"} shows the additional endpoint of any GI bleeding. No statistically significant interaction between treatment and PPI use at baseline was observed comparing dabigatran dual therapy with warfarin triple therapy (interaction *p* values 0.84 and 0.62 for dabigatran 110 and 150 mg dual therapy, respectively).Fig. 3Gastrointestinal bleeding in patients receiving/not receiving proton pump inhibitors (PPIs) at baseline: dabigatran 110 mg and 150 mg dual therapy vs warfarin triple therapy. For the comparison with 150 mg dabigatran dual therapy, elderly patients outside the USA are excluded. Statistics as in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}, respectively. *CI* confidence interval, *HR* hazard ratio

The results from multivariable-adjusted Cox models are similar to those in Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"} (*p* values for interaction \> 0.05, Table [2](#Tab2){ref-type="table"}). Importantly, the multivariable-adjusted hazard ratios of GI bleeding for dabigatran 110 mg dual therapy vs warfarin triple therapy were 0.82 (95% confidence interval \[CI\] 0.42--1.59) for patients using PPIs and 0.70 (95% CI 0.29--1.71) for those not using PPIs (*p*-interaction = 0.78); the hazard ratios for the comparison between dabigatran 150 mg dual therapy and warfarin triple therapy were, respectively, 0.83 (95% CI 0.36--1.91) and 0.71 (95% CI 0.25--2.06) \[*p*-interaction = 0.81\]. Table 1 of the ESM shows the same analyses as in Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"} but restricted to patients taking clopidogrel (87% of the population). Similar to that global population's results, the *p* values obtained for interaction were all \> 0.05. Specifically for GI bleeding, the *p* values for interaction were 0.61 for the comparison between dabigatran 110 mg dual therapy and warfarin triple therapy and 0.35 for the comparison between dabigatran 150-mg dual therapy and warfarin triple therapy.

Influence of Proton Pump Inhibitor Utilization at Baseline on the Bleeding and Clinical Efficacy Composite Endpoint in the Whole Population (Study Treatment-Independent Analysis) {#Sec7}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In an additional analysis, we evaluated event rates for the whole population among patients treated or not treated with PPIs, by means of both univariable and multivariable models. The univariable analyses showed hazard ratios \[HRs; 95% CIs of 1.00 (0.84--1.18), 1.12 (0.82--1.52), 1.23 (0.81--1.89), and 1.20 (0.96--1.48)\] for ISTH MBE/CRNMBE, ISTH MBE alone, GI bleeding, and DTE/unplanned revascularization, respectively. The multivariable-adjusted analyses showed similar results, with HRs (95% CIs) of 0.93 (0.78--1.12) for ISTH MBEs/CRNMBEs, 1.13 (0.72--1.77) for GI bleeding, and 1.16 (0.92--1.45) for the clinical efficacy composite endpoint (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Safety and efficacy outcomes in patients receiving/not receiving proton pump inhibitors (PPIs) at baseline: study treatment-independent multivariable analyses. Hazard ratios (HRs) and confidence intervals (CIs) from a stratified Cox proportional hazard regression analysis. See Sect. [2.2](#Sec4){ref-type="sec"} for details. *CRNMBE* clinically relevant non-major bleeding event, *DTE* death/thromboembolic event, *ISTH* International Society on Thrombosis and Haemostasis, *MBE* major bleeding event

Discussion {#Sec8}
==========

In this prespecified analysis of the RE-DUAL PCI trial \[[@CR16]\] in patients with AF undergoing PCI, the benefit of dual antithrombotic therapy with dabigatran 110 or 150 mg twice daily in reducing the risk of MBEs or CRNMBEs, when compared with triple therapy with warfarin, did not appear to be influenced by use of a PPI at baseline. As such, dual therapy with both dosages of dabigatran did not seem to differ from warfarin triple therapy in terms of the risk of experiencing DTE or unplanned revascularization, also irrespective of PPI administration.

A meta-analysis comparing dual with triple antithrombotic therapy in 5317 patients from four randomized controlled trials (including RE-DUAL PCI) showed that dual therapy led to lower risks of major or minor bleeding (HR, 0.53; 95% CI 0.36--0.85) per Thrombolysis in Myocardial Infarction (TIMI) Study Group criterion, with comparable risk of major adverse cardiovascular events (HR 0.85; 95% CI 0.48--1.29) \[[@CR18]\]. More recently, a network meta-analysis of 10,026 patients from four trials (including RE-DUAL PCI) reported odds ratios for TIMI major bleeding of 0.49 (95% CI 0.30--0.82) for DOAC plus a P2Y12 inhibitor, 0.58 (95% CI 0.31--1.08) for a vitamin K antagonist plus a P2Y12 inhibitor, and 0.70 (95% CI 0.38--1.23) for DOAC plus DAPT, compared to a vitamin K antagonist plus DAPT as reference \[[@CR19]\]. There was no significant difference in the risk of major adverse cardiovascular events \[[@CR19]\].

To our knowledge, ours is the first study to investigate PPI use in patients receiving triple vs dual antithrombotic therapy with DOACs. In patients taking DAPT without anticoagulants, previous reports found that the use of PPIs significantly reduces the risk of GI bleeding \[[@CR10], [@CR20]--[@CR22]\]. Similarly, a retrospective cohort analysis with patients using warfarin and aspirin suggested that PPI use was associated with a lower risk of upper GI bleeding hospitalization (adjusted HR 0.51; 95% CI 0.27--0.97), with a tendency of benefit for patients taking warfarin and a P2Y12 inhibitor (HR 0.54; 95% CI 0.29--1.01) \[[@CR11]\]. In a large Medicare population taking an anticoagulant agent (very few with concomitant antiplatelet therapy), PPI use was associated with lower rates of hospitalization for upper GI bleeding when coadministered with both warfarin and DOACs, including dabigatran (incidence rate ratio for dabigatran: 0.49; 95% CI 0.41--0.59) \[[@CR12]\].

The COMPASS trial analyzed \> 17,000 patients randomized to pantoprazole 40 mg daily or placebo on top of rivaroxaban and aspirin or monotherapy with each drug. In a 3-year follow-up, similar rates of the composite endpoint of cardiovascular deaths, myocardial infarction, or stroke were found for pantoprazole or the placebo groups \[[@CR23]\]. The drug was generally well tolerated, with the exception of a significant 33% increase in the incidence of enteric infection. There were no significant differences between pantoprazole or placebo regarding upper GI events globally, or in other analyzed bleeding parameters, with the exception of "overt bleeding of GI origin confirmed by endoscopy of radiography" (annual rate of 0.060% for pantoprazole vs 0.12% for placebo, *p* = 0.03) \[[@CR24]\].

In the RE-LY trial, dabigatran 150 mg twice daily was associated with higher rates of GI bleeding compared with warfarin, which was not observed with dabigatran 110 mg \[[@CR25]\]. Dabigatran is administered as a prodrug (dabigatran etexilate) and only 3--7% is absorbed into the systemic circulation \[[@CR26], [@CR27]\]. The remaining non-absorbed prodrug may also undergo intraluminal activation by gut esterases, which may lead to bleeding owing to a topic effect on the intestinal mucosa \[[@CR28], [@CR29]\]. Conversely, bleeding events caused by antiplatelet drugs and warfarin are observed mainly in the upper GI tract \[[@CR10], [@CR30]\]. Given these differences in anatomic sites of bleeding, PPIs would be expected to have a more significant role in bleeding prevention for patients treated with warfarin triple therapy than patients receiving dabigatran dual therapy. Nevertheless, contrary to this rationale, our analysis suggests that, even when receiving a PPI, patients in the warfarin triple-therapy group did not show lower GI bleeding rates than patients prescribed dabigatran dual therapy, with a numerically lower risk for patients utilizing PPIs with dabigatran 110 mg dual therapy, in comparison with warfarin triple therapy plus PPIs (HR of 0.66).

Regarding clinical efficacy (DTE/unplanned revascularization), PPIs may reduce absorption of dabigatran \[[@CR31], [@CR32]\], and concerns have been raised that PPIs could reduce the conversion of clopidogrel (the most commonly used P2Y12 inhibitor in RE-DUAL: 87%) into its active metabolite, \[[@CR31]\] despite that in RE-DUAL the benefits of dabigatran 110 mg or 150 mg dual therapy in comparison with warfarin triple therapy in decreasing bleeding risks were consistent across patients treated with clopidogrel or ticagrelor. \[[@CR33]\] Proton pump inhibitors could also have a deleterious impact in vascular function per se \[[@CR9]\]. All these theoretical effects could eventually lead to a higher incidence of clinical efficacy endpoints in patients treated with a PPI \[[@CR4], [@CR34], [@CR35]\].

In the present study, in the dabigatran 110-mg subgroup, a HR of 1.30 was observed for patients taking PPIs vs not taking PPIs, but this trend was not observed in the dabigatran 150-mg subgroup. Thus, no consistent difference between treatment groups was seen. However, despite that no significant interactions were observed in the subgroup of patients taking clopidogrel, a HR of 1.45 was observed in the population on dabigatran 110 mg, but this trend was not observed in the dabigatran 150 mg subgroup; this finding could be related to an interaction between PPI and clopidogrel \[[@CR7]\], leading to an increase in clinical events in the dabigatran 110 mg subgroup that was blunted with the dabigatran 150 mg doses. However, we urge caution because this one finding is in a subgroup of a subgroup, and the interaction *p* value is not statistically significant, thus indicating that this cannot be determined from this dataset.

Limitations {#Sec9}
-----------

Our results should be interpreted in the context of a subgroup analysis of a randomized trial in a setting with very few data available from other sources. The RE-DUAL PCI trial was not powered for any subgroup analysis and no adjustment for multiplicity was performed, thus the reported results should be regarded as exploratory. As in all publications with similar characteristics, there are imbalances in the baseline characteristics of patients taking vs not taking PPIs, and differences in baseline characteristics were previously acknowledged as a possible source of bias when analyzing the effect of PPI therapy on cardiovascular outcomes \[[@CR4]\]. Second, we did not have information about the time using a PPI during follow-up, which may limit assessment of the influence of PPI intake on long-term bleeding and cardiovascular outcomes. Third, more granular data regarding PPI brand and dosage were not available, limitations that are shared with similar analyses \[[@CR12]\]. Finally, we did not retrieve information about upper vs lower GI bleeding, which could be useful to better understand potential interactions between PPIs, DOAC use, and bleeding.

Conclusions {#Sec10}
===========

Dual therapy with dabigatran at both 110- and 150-mg doses twice daily reduced the risk of bleeding when compared with warfarin triple therapy, regardless of PPI use at baseline in patients with AF undergoing PCI. The risk of clinical efficacy endpoints appeared similar with dabigatran dual therapy vs warfarin triple therapy irrespective of PPI utilization.
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